Aleksandra Butrym
Overview
Explore the profile of Aleksandra Butrym including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lacina P, Porzuczek D, Bogunia-Kubik K, Mazur G, Butrym A
Dent Med Probl
. 2024 Dec;
61(6):885-892.
PMID: 39704419
Background: Multiple myeloma (MM) is a hematological malignancy characterized by the presence of abnormal plasma cells. It is associated with anemia, bone lesions and renal dysfunction. Immunomodulatory drugs (IMiDs) are...
2.
Madry K, Lis K, Sienkiewicz E, Drozd-Sokolowska J, Biecek P, Sosnia O, et al.
Front Oncol
. 2024 Jun;
14:1404322.
PMID: 38939343
Introduction: Infections represent one of the most frequent causes of death of higher-risk MDS patients, as reported previously also by our group. Azacitidine Infection Risk Model (AIR), based on red...
3.
Zielinska P, Wieczorkiewicz-Kabut A, Bialas K, Koclega A, Gruenpeter K, Kopinska A, et al.
Ann Hematol
. 2024 Jun;
103(8):3095-3104.
PMID: 38878171
Haploidentical stem cell transplantation (haplo-SCT) using post-transplantation cyclophosphamide (post-Cy) is considered a reasonable therapeutic option for patients who lack matched donor or who urgently need transplant procedure due to high...
4.
Dratwa M, Lacina P, Butrym A, Porzuczek D, Mazur G, Bogunia-Kubik K
Sci Rep
. 2023 Sep;
13(1):15792.
PMID: 37737335
Telomere dysfunction is a notable event observed in many cancers contributing to their genomic instability. A major factor controlling telomere stability is the human telomerase reverse transcriptase catalytic subunit (hTERT)....
5.
Charlinski G, Grzasko N, Bolkun L, Sawicki W, Paczkowska E, Druzd-Sitek A, et al.
J Oncol Pharm Pract
. 2023 Sep;
30(7):1144-1151.
PMID: 37728209
Introduction: Therapeutic adherence (TA) is one of the most important factors influencing the effectiveness of treatment. Oral anti-cancer drugs are increasingly used to treat malignancy including multiple myeloma (MM). Our...
6.
Macauda A, Briem K, Clay-Gilmour A, Cozen W, Forsti A, Giaccherini M, et al.
Leukemia
. 2023 Sep;
37(11):2326-2329.
PMID: 37723249
No abstract available.
7.
Clavero E, Sanchez-Maldonado J, Macauda A, Ter Horst R, Sampaio-Marques B, Jurczyszyn A, et al.
Int J Mol Sci
. 2023 May;
24(10).
PMID: 37239846
Multiple myeloma (MM) arises following malignant proliferation of plasma cells in the bone marrow, that secrete high amounts of specific monoclonal immunoglobulins or light chains, resulting in the massive production...
8.
Cabrera-Serrano A, Sanchez-Maldonado J, Ter Horst R, Macauda A, Garcia-Martin P, Benavente Y, et al.
Int J Mol Sci
. 2023 May;
24(9).
PMID: 37175717
Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults worldwide. Although genome-wide association studies (GWAS) have uncovered the germline genetic component underlying CLL susceptibility, the potential use of...
9.
Kus A, Wieczorek S, Dybko J, Szymczyk-Nuzka M, Butrym A, Makuch S, et al.
Eur J Clin Invest
. 2022 Dec;
53(2):e13928.
PMID: 36453977
No abstract available.
10.
Kopinska A, Weglarz P, Koclega A, Wieczorkiewicz-Kabut A, Wozniczka K, Armatys A, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Nov;
23(1):28-39.
PMID: 36323603
Introduction: Patients with relapsed/refractory acute myeloid leukemia (r/r AML) are characterized as having a poor prognosis. The only viable option of treatment for these patients is allogenic stem cell transplantation...